Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Cleary, Catherine; Jungkim, S.; Ravikumar, Kushal; Kelliher, Clare; Acheson, R W; Hickey-Dwyer, Marie

doi:10.1038/sj.eye.6702936

Cited by 72 publications

(61 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…20 There have also been reports of the full-length, monoclonal anti-VEGF antibody bevacizumab (Avastin s ; Genentech), which is approved for certain solid tumours (ie, metastatic colorectal cancer, non-small-cell lung cancer, breast cancer), administered as intravitreal injection in patients with neovascular AMD. [21][22][23][24][25][26][27][28] Findings from these small-scale, short-term, noncontrolled, non-randomized studies or case series have shown improvements in visual acuity of 3.1-7.4 letters from baseline over 1-12 months follow-up, as well as anatomical benefits, following bevacizumab. [21][22][23][24][25] Although bevacizumab was generally well tolerated, adverse events included endophthalmitis, retinal pigment epithelial tears, and submacular haemorrhage.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study

Soubrane

Harding

Wolf

et al. 2008

Eye

View full text Add to dashboard Cite

Therapy in Occult-Only Lesions (POOL) Study Group AbstractPurpose To provide further information on verteporfin photodynamic therapy in occult with no classic choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD). Methods Verteporfin therapy was administered at baseline and then at months 3, 6, and 9, if fluorescein leakage from CNV was evident on angiography. Results Of 202 patients enrolled, 184 completed 12 months. Each patient was treated in one eye only. All study eyes received verteporfin therapy at baseline, with a progressive decrease in the number treated at subsequent visits (mean 2.5 treatments during 12 months). The mean change in visual acuity letter score from baseline to month 12 was À11.9. At month 12, 164 eyes (82.4%) had lost o30 letters of visual acuity, 123 eyes (61.8%) had lost o15 letters, 78 eyes (39.2%) had lost o5 letters, 31 (15.6%) had 45-letter increase, and 7 (3.5%) had 415-letter improvement. The percentage of eyes with fluorescein leakage from CNV decreased from 75.5% at month 3 to 25.1% at month 12. Adverse events were documented for 54% patients. Few patients had treatment-associated adverse events (7%). Acute severe visual acuity decrease occurred in two eyes (1%), one of which had visual acuity that returned to baseline by the next follow-up visit.Conclusions This study provides additional evidence that over 12 months, verteporfin is generally well tolerated and maintains or improves visual acuity in over one-third of eyes containing occult-only CNV. Verteporfin also improved anatomical outcomes by reducing leakage from CNV in at least two-thirds of eyes.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[21][22][23][24][25] Although bevacizumab was generally well tolerated, adverse events included endophthalmitis, retinal pigment epithelial tears, and submacular haemorrhage. 21,26,28 The long-term efficacy and safety of bevacizumab in neovascular AMD have yet to be elucidated in large-scale, randomized, controlled trials.…”

Section: Discussionmentioning

confidence: 99%

Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study

Soubrane

Harding

Wolf

et al. 2008

Eye

View full text Add to dashboard Cite

show abstract

“…O primeiro paciente com MNVSR secundária a DMRI tratado com bevacizumabe intravítreo (1mg, dose única) apresentou redução da espessura retiniana e diminuição da metamorfopsia (39) . Outros estudos retrospectivos (40)(41)(42)(43)(44)(45)(46)(47)(48)(49)(50)(51)(52)(53)(54) e prospectivos (55)(56)(57)(58)(59)(60)(61)(62)(63)(64)(65) foram publicados, com doses de bevacizumabe variando de 1 a 1,5mg para o tratamento de DMRI exsudativa. Todos demonstraram melhora estatisticamente significante da AV, melhora do padrão angiográfico, resolução do edema da retina em até 90% dos casos e uma boa margem de segurança do tratamento.…”

Section: Bevacizumabeunclassified

Tratamento da DMRI exsudativa: revisão das drogas antiangiogênicas

Filho¹,

Penha²,

Garcia³

2012

Rev. bras.oftalmol.

View full text Add to dashboard Cite

RESUMODegeneração Macular Relacionada à Idade (DMRI) exsudativa é a principal causa de perda visual severa em indivíduos acima de 50 anos nos países desenvolvidos. O fator de crescimento endotelial (VEGF) é considerado um dos mais importantes reguladores da angiogênese e da permeabilidade vascular . Drogas com atividade antiVEGF tem se mostrado eficaz em preservar ou melhorar a acuidade visual (AV) ao inibir a permeabilidade vascular e o crescimento neovascular nos pacientes tratados. Este artigo de revisão descreve o atual uso terapêutico das medicações antiVEGF para DMRI exsudativa e fornece uma visão geral do futuro da terapia antiangiogênica.Descritores: Degeneração macular/quimioterapia; Fator idade; Neovascularização de coróide/quimioterapia; Acuidade visual/fisiologia; Fator A de crescimento do endotélio vascular/antagonistas & inibidores; Inibidores da angiogênese/uso terapêutico ABSTRACT Neovascular age-related macular degeneration is the leading cause of severe, irreversible vision loss in individuals over 50 years in developed countries. Vascular endothelial growth factor (VEGF) has been shown to play a role in the regulation of choroidal neovascularization and vascular permeability. Anti-VEGF drugs have been shown to preserve or improve visual acuity by inhibiting vascular permeability and arresting the growth of neovascularization in the vast majority of treated patients. This review describes the current literature on the use of this therapeutic approach in the management of neovascular AMD and gives an overview of the future directions.

show abstract

“…No es un fármaco con indicación aprobada para uso intraocular, ni para el tratamiento de la DMAE húmeda; sin embargo, la experiencia acumulada con miles de pacientes en los últimos años, y los resultados de múltiples series publicadas en revistas con índice de impacto alto, demuestran que el bevacizumab (Avastin ® ) puede aportar un beneficio más próximo a los resultados obtenidos con el ranibizumab que a los obtenidos con la terapia fotodinámi-ca y el pegaptanib (29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40).…”

Section: Bevacizumabunclassified

Guías de práctica clínica de la SERV: Tratamiento de la degeneración macular asociada a la edad (DMAE) exudativa

Ruiz-Moreno

Arias

Armadá-Maresca

et al. 2009

Arch Soc Esp Oftalmol

View full text Add to dashboard Cite

RESUMENObjetivo: La Degeneración Macular Asociada a la Edad (DMAE) en su forma húmeda supone una grave enfermedad que condiciona ceguera legal en muchos pacientes y con mal pronóstico si no es tratada. Pretendemos establecer una guía de actuación clínica con las diferentes opciones terapeúticas que existen en el momento actual, que puedan ayudar al oftalmólogo en su práctica clínica. Métodos: Un grupo de expertos en retina médica seleccionados por la SERV han evaluado los resultados de los diferentes estudios publicados con los fármacos actualmente disponibles, llegando a un ABSTRACT Objective: Age related macular degeneration (ARMD) in its neovascular form is a serious disease which produces legal blindness in many patients with poor prognosis if left untreated. We intend to establish a clinical guide with the different therapeutic options that exist nowadays, which may help the ophthalmologists in their clinical practice. Methods: A group of medical retina experts selected by SERV have evaluated the results of different published studies with the drugs currently available, obtaining an evidence-based consensus. Some recommendations have been established for diagno-

show abstract

Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results

Cited by 72 publications

References 10 publications

Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study

Verteporfin therapy in occult with no classic CNV due to AMD: results of the Photodynamic Therapy in Occult-Only Lesions study

Tratamento da DMRI exsudativa: revisão das drogas antiangiogênicas

Guías de práctica clínica de la SERV: Tratamiento de la degeneración macular asociada a la edad (DMAE) exudativa

Contact Info

Product

Resources

About